Skip to content

Asset turnover at other companies

Intuitive Surgical logo
Intuitive SurgicalISRG
0.5×0.0×
Theravance Biopharma logo
Theravance BiopharmaTBPH
0.3×+0.1×
LQD
Liquidia CorporationLQDA
0.9×+0.8×
United Therapeutics logo
United TherapeuticsUTHR
0.4×0.0×
Viemed Healthcare, Inc. logo
Viemed Healthcare, Inc.VMD
1.5×+0.1×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
0.5×+0.3×

Other financials

Income statement

See full
Revenue$20.6M-8.7%
Gross profit$16.0M-1.8%
Operating income-$13.0M+11.0%
Net income-$13.7M+5.5%
EPS (diluted)-$0.33+8.3%

Balance sheet

See full
Cash & equivalents$61.0M-2.4%
Total debt$56.3M-1.2%
Total equity$45.8M-41.1%
Total assets$120.0M-20.4%

Cash flow

See full
Operating cash flow-$10.1M+23.6%
CapEx$9.0K-97.0%
Free cash flow-$10.1M+25.3%

Valuation

See full
Market cap$54.91M-43.7%
Enterprise value$50.17M-39.2%
P/S0.6×-0.5×

Profitability

See full
Gross margin75.5%+2.0pp
Operating margin-58.8%-5.8pp
Net margin-60.1%-4.4pp
FCF margin-33.2%-4.4pp

Returns & leverage

See full
Return on equity-86.2%+62.6pp
Debt / equity1.2×+0.5×
Current ratio4.9×-0.1×

Where this comes from

Calculated from Pulmonx Corporation’s reported figures.

Based on trailing twelve months.

The official record: Pulmonx Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulmonx Corporation's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pulmonx Corporation's asset turnover?
Pulmonx Corporation (LUNG) reported asset turnover of 0.7× in Q1 2026.
How has Pulmonx Corporation's asset turnover changed year-over-year?
Pulmonx Corporation's asset turnover increased by 17.9% year-over-year, from 0.6× to 0.7×.
What is the long-term trend for Pulmonx Corporation's asset turnover?
Over 5 years (2020 to 2025), Pulmonx Corporation's asset turnover has grown at a 24.6% compound annual growth rate (CAGR), from 0.2× to 0.6×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.